Research Programme: small molecule inhibitors - Eli Lilly and Company/PRISM BioLab
Latest Information Update: 03 Jan 2024
At a glance
- Originator PRISM BioLab
- Developer Eli Lilly and Company; PRISM BioLab
- Class Antifibrotics; Antineoplastics; Peptidomimetics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Cancer; Fibrosis